Statistical issues in randomized trials of cancer screening

BMC Medical Research Methodology

Volumn 2, Issue , 2002, Pages 1-7

  Baker, Stuart G ^a   Kramer, Barnett S ^b   Prorok, Philip C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; METHODOLOGY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; BIOASSAY; HUMAN; MORTALITY; NEOPLASM; PATIENT SELECTION; PRACTICE GUIDELINE; STATISTICS; TIME; TREATMENT REFUSAL;

ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT REFUSAL;

EID: 0242476257     PISSN: 14712288     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2288-2-11     Document Type: Article

References (25)

1. Etzioni RD, Connor RJ, Prorok PC, Self SG: Design and analysis of cancer screening trials. Statistical Methods in Medical Research 1995, 4:3-17
2. Connor RJ, Prorok PC: Issues in the mortality analysis of randomized controlled trials of cancer screening. Controlled Clinical Trials 1994, 15:81-99
3. Black WC, Haggstrom DA, Welch HG: All-cause mortality in randomized trials of cancer screening. Journal of the National Cancer Institute 2002, 94:167-173
4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472-1477
5. Glasziou PP: Meta-analysis adjusting for compliance: The example of screening for breast cancer. Journal of Clinical Epidemiology 1992, 1251-1256
6. Baker SG, Lindeman KS: The paired availability design: A proposal for evaluating epidural analgesia during labor. Statistics in Medicine 1994, 13:2269-2278
7. Angrist JD, Imbens GW, Rubin DR: Identification of causal effects using instrumental variables. Journal of the American Statistical Association 1996, 92:444-455
8. Baker SG: Analysis of survival data from a randomized trial with all-or-none compliance; estimating the cost-effectiveness of a cancer screening program. Journal of the American Statistical Association 1998, 93:929-934
9. Cuzick J, Edward R, Segnan N: Adjusting for non-compliance and contamination in randomized clinical trials. Statistics in Medicine 1997, 16:1017-1029
10. McIntosh MW: Instrumental variables when evaluating screening trials: estimating the benefit of detecting cancer by screening. Stat Med 1999, 19:2775-2794
11. Zelen M: A new design for randomized clinical trials. New England Journal of Medicine 1979, 300:1242-1145
12. Shaprio S, Venet W, Strax P, Venet L: Periodic Screening for Breast Cancer, The Health Insurance Plan Project and Its Sequelae, 1963-1986, Baltimore, Johns Hopkins University Press 1988
13. Etzioni R, Self SG: On the catch-up time method for analyzing cancer screening trials. Biometrics 1995, 51:31-43
14. Self SG, Etzioni R: A likelihood ratio test for cancer screening trials. Biometrics 1995, 51:44-50
15. Buyske S, Fagerstrom R, Ying Z: A class of weighted log-rank tests for survival data when the event is rare. Journal of the American Statistical Association 2000, 95:249-258
16. Hu P, Zelen M: Planning clinical trials to evaluate early detection programmes. Biometrka 1997, 84:817-829
17. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. Journal of the National Cancer Institute 1994, 86:829-835
18. Efron B, Gong G: A leisurely look at the bootstrap, the jack-knife, and cross-validation. American Statistician 1983, 37:36-48
19. Baker SG, Kramer BS, Srivastava S: Markers for early detection of cancer: Statistical issues for nested case-control studies. BMC Medical Research Methodology 2002, 2:4 [http://www.biomedcentral.com/1471-2288/2/4/]
20. Baker SG, Tockman MS: Evaluating serial observations of pre-cancerous lesions for further study as a trigger for early intervention. Stat Med 2002, 21:2383-2390
21. Pepe MS, Etzioni R, Feng S, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 2001, 93:1054-1061
22. Cronin KA, Weed DL, Connor RJ, Prorok PC: Case-control studies of cancer screening: Theory and practice. Journal of the National Cancer Institute 1998, 90:498-504
23. Baker SG: Evaluating the age to begin periodic breast cancer screening using data from a few regularly scheduled screens. Biometrics 1998, 54:1569-1578
24. Baker SG: Evaluating periodic cancer screening without a randomized control group: a simplified design and analysis. In: Quantitative Methods for the Evaluation of Cancer Screening, (Edited by: Duffy SW, Hill C, Esteve J) London: Edward Arnold Limited, 2001, 34-41
25. Baker SG, Lindeman KL, Kramer BS: The paired availability design for historical controls BMC Medical Research Methodology 2001, 1:9 [http://www.biomedcentral.com/1471-2288/1/9]